• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Quince Therapeutics Inc.

    7/17/23 11:07:49 AM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $QNCX alert in real time by email
    SC 13G 1 doc1.htm NONE Schedule 13G


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
    (Amendment No. n/a )*
     
    Quince Therapeutics, Inc. 

    (Name of Issuer)
     
    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     
    22053A107

    (CUSIP Number)
     
    July 06, 2023

    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
         o  Rule 13d-1(b)
     
         x  Rule 13d-1(c)
     
         o  Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


     
     

     
     
    CUSIP No.  22053A107      
     
          
    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
     BML Investment Partners, L.P.
       
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a)   o
     (b)   x
       
    3 SEC USE ONLY
      
      
       
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
      
     Delaware
        
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER
      
     0
       
    6 SHARED VOTING POWER
      
     1466201
       
    7 SOLE DISPOSITIVE POWER
      
     0
       
    8 SHARED DISPOSITIVE POWER
      
     1466201
       
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      
     1466201
       
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      
     o
       
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
      
     4.04%
       
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      
     PN
     

    FOOTNOTES
      
     BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M. Leonard. As a result, Braden M. Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b)(1) of the Exchange Ac
     
     

     
     
    CUSIP No.  22053A107      
     
          
    1 NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
     Braden M Leonard
       
    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a)   o
     (b)   x
       
    3 SEC USE ONLY
      
      
       
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
      
     United States
        
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER
      
     375100
       
    6 SHARED VOTING POWER
      
     1466201
       
    7 SOLE DISPOSITIVE POWER
      
     375100
       
    8 SHARED DISPOSITIVE POWER
      
     1466201
       
    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
      
     1841301
       
    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
      
     o
       
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
      
     5.07%
       
    12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
      
     IN
     

    FOOTNOTES
      
     BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M. Leonard. As a result, Braden M. Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b)(1) of the Exchange Act.
     
     

     
     
    Item 1.

     
    (a)
    Name of Issuer
     
     
    Quince Therapeutics, Inc.

     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    601 Gateway Boulevard, Suite 1250, South San Francisco, CA 94080

    Item 2.

     
    (a)
    Name of Person Filing
     
     
    BML Investment Partners, L.P.

     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    65 Cedar - Suite 2
    Zionsville, IN 46077

     
    (c)
    Citizenship
     
     
    Delaware

     
    (d)
    Title of Class of Securities
     
     
    Common Stock, par value $0.001 per share

     
    (e)
    CUSIP Number
     
     
    22053A107

     
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     
    (a)
    o
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     
    (b)
    o
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     
    (c)
    o
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     
    (d)
    o
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     
    (e)
    o
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     
    (f)
    o
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     
    (g)
    o
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     
    (h)
    o
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     
    (i)
    o
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     
    (j)
    o
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).

     
    (k)
    o
    A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     
     
     

     
     
    Item 4.
    Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     
    (a)
    Amount beneficially owned: 1,841,301

     
    (b)
    Percent of class: 5.07%

     
    (c)
    Number of shares as to which the person has:

     
    (i)
    Sole power to vote or to direct the vote: 375,100

     
    (ii)
    Shared power to vote or to direct the vote: 1,466,201

     
    (iii)
    Sole power to dispose or to direct the disposition of: 375,100

     
    (iv)
    Shared power to dispose or to direct the disposition of: 1,466,201

    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o .
     
    N/A
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
     
    N/A
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
     
    N/A
     
    Item 8.
    Identification and Classification of Members of the Group
     
    N/A
     
    Item 9.
    Notice of Dissolution of Group
     
    N/A
     
     
     

     
     
     
    Item 10.
    Certification
      
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
     
     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
     
     BML Capital Management, LLC
     
        
    Date: July 17, 2023
    By:
    /s/  Braden M Leonard 
       Name: Braden M Leonard 
       Title:  Managing Member 
        
     
     
     
      
        
    Date: July 17, 2023
    By:
    /s/  Braden M Leonard 
       Name: Braden M Leonard 
       
        
     
    Footnotes:
    BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M.Leonard. As a result, Braden M.Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b) (1) of the Exchange Act.

    Attention:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
     
     


    Get the next $QNCX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QNCX

    DatePrice TargetRatingAnalyst
    8/5/2025$9.00Mkt Outperform
    Citizens JMP
    3/24/2025$10.00Outperform
    Oppenheimer
    More analyst ratings

    $QNCX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Quince Therapeutics Inc.

    SCHEDULE 13G - Quince Therapeutics, Inc. (0001662774) (Subject)

    8/14/25 4:33:22 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Quince Therapeutics Inc.

    10-Q - Quince Therapeutics, Inc. (0001662774) (Filer)

    8/11/25 4:06:02 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Quince Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

    8/11/25 4:05:35 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $QNCX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

    Marks major milestone with completion of enrollment in pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T; topline results expected in first quarter of 2026 Closed financing priced at a premium bringing existing cash position to approximately $35 million; expected to provide runway through Phase 3 topline results and into at least second quarter of 2026 Entered into strategic relationship with Option Care Health to support commercial launch of eDSP in the U.S. Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an

    8/11/25 4:05:00 PM ET
    $OPCH
    $QNCX
    Medical/Nursing Services
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP

    Provides access to broad-reaching nationwide network of specialty pharmacy and ambulatory infusion suites across the U.S. Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that it has formed a strategic relationship with Option Care Health, Inc. (NASDAQ:OPCH), the nation's largest independent provider of home and ambulatory infusion services, to support the commercial development and efficient launch of Quince's lead asset, encapsulated dexamethasone sodium phosphate (eDSP) in the U.S., assuming positive study results and subsequent regulatory approval.

    8/7/25 8:00:00 AM ET
    $OPCH
    $QNCX
    Medical/Nursing Services
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

    Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that the company has completed enrollment in its pivotal Phase 3 NEAT (Neurological Effects of eDSP on Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial to evaluate its lead asset, eDSP, for the treatment of the rare neurodegenerative disease Ataxia-Telangiectasia (A-T). Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, "The completion of enrollment in our pivotal Phase 3 NEAT clinical trial evaluating eDSP for the treatment of A-T is a major milestone for Quin

    7/16/25 8:00:00 AM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $QNCX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citizens JMP initiated coverage on Quince Therapeutics with a new price target

    Citizens JMP initiated coverage of Quince Therapeutics with a rating of Mkt Outperform and set a new price target of $9.00

    8/5/25 7:12:02 AM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Oppenheimer initiated coverage on Quince Therapeutics with a new price target

    Oppenheimer initiated coverage of Quince Therapeutics with a rating of Outperform and set a new price target of $10.00

    3/24/25 8:40:42 AM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $QNCX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CBO, COO & CCO Hannah Brendan was granted 37,736 shares, increasing direct ownership by 13% to 334,276 units (SEC Form 4)

    4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

    6/23/25 8:48:00 AM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President Ryan Charles S. was granted 7,548 shares, increasing direct ownership by 6% to 130,009 units (SEC Form 4)

    4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

    6/23/25 8:46:04 AM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO and CMO Thye Dirk was granted 150,944 shares, increasing direct ownership by 18% to 994,885 units (SEC Form 4)

    4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

    6/23/25 8:43:12 AM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $QNCX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO AND CHIEF MEDICAL OFFICER Thye Dirk bought $107,375 worth of shares (154,500 units at $0.69), increasing direct ownership by 22% to 843,941 units (SEC Form 4)

    4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

    9/3/24 5:38:44 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PRESIDENT Ryan Charles S. bought $31,452 worth of shares (48,387 units at $0.65), increasing direct ownership by 65% to 122,461 units (SEC Form 4)

    4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

    8/22/24 5:51:16 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF BUSINESS OFFICER AND COO Hannah Brendan bought $24,166 worth of shares (38,924 units at $0.62), increasing direct ownership by 15% to 296,540 units (SEC Form 4)

    4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

    8/21/24 6:38:07 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $QNCX
    Financials

    Live finance-specific insights

    View All

    Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan

    Quince Therapeutics, Inc. (NASDAQ:QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced that its Board of Directors (the "Board") unanimously approved the adoption of a limited duration stockholder rights plan (the "Rights Plan") and declared a dividend distribution of one preferred share purchase right on each outstanding share of Quince's common stock. The dividend distribution will be made on April 17, 2023, payable to stockholders of record on that date, and is not taxable to stockholders. The Rights Plan is effective immediately and has a one-year duration, expiring on April 5, 2024.

    4/5/23 4:05:00 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $QNCX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Quince Therapeutics Inc.

    SC 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)

    11/14/24 4:00:05 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D filed by Quince Therapeutics Inc.

    SC 13D - Quince Therapeutics, Inc. (0001662774) (Subject)

    11/13/24 9:17:26 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Quince Therapeutics Inc.

    SC 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)

    8/6/24 8:04:44 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $QNCX
    Leadership Updates

    Live Leadership Updates

    View All

    Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

    Marks major milestone with completion of enrollment in pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T; topline results expected in first quarter of 2026 Closed financing priced at a premium bringing existing cash position to approximately $35 million; expected to provide runway through Phase 3 topline results and into at least second quarter of 2026 Entered into strategic relationship with Option Care Health to support commercial launch of eDSP in the U.S. Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an

    8/11/25 4:05:00 PM ET
    $OPCH
    $QNCX
    Medical/Nursing Services
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

    Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the appointment of Dr. Hassan Abolhassani, Assistant Professor of Clinical Immunology and Research Specialists in the Department of Medical Biochemistry and Biophysics at the Karolinska Institutet in Stockholm, Sweden, to the company's Scientific Advisory Board (SAB). Dr. Abolhassani becomes the ninth member to join Quince's SAB, which is comprised of leading experts in Ataxia-Telangiectasia (A-T), biochemistry, neurology, immunology, genetic, hematology, pharmacology, and clinical practice. Dr. Mauro Magnani,

    7/10/25 4:05:00 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Quince Therapeutics Appoints Renowned Pediatric Neurologist Dr. William Whitehouse to Scientific Advisory Board

    Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the appointment of Dr. William Whitehouse, Honorary Clinical Associate Professor of the School of Medicine at the University of Nottingham, and recently retired Consultant Paediatric Neurologist at Nottingham Children's Hospital, Nottingham University Hospitals NHS Trust, to the company's Scientific Advisory Board (SAB). Dr. Whitehouse joins seven founding members of Quince's SAB comprised of leading experts in biochemistry, neurology, immunology, hematology, pharmacology, and clinical practice. Dr. Mauro Magn

    1/23/25 4:05:00 PM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care